Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP ‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials
Obesity · 2026-04 · 34 (4) · 770-781
DOI: 10.1002/oby.70100 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Obesity, online erschienen am 01.12.2025. Verfasst von Lucas Sabatella und 9 weiteren Autor:innen. Beteiligte Einrichtung: Obesity Unit, Department of General Surgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Bariatric Surgery, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity.
Methods
A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults with overweight or obesity. Primary outcomes were percent total weight loss (TWL) and BMI; secondary outcomes included body weight, waist circumference, HbA1c, and systolic blood pressure. Random‐effects models used lifestyle intervention as the common comparator; all MBS versus GLP‐1 RA comparisons were indirect.
Results
Thirty randomized controlled trials ( n = 20,015) were included. At < 104 weeks, MBS achieved greater reductions than GLP‐1 RAs in %TWL (ETD –10.3%; p = 0.001), BMI (−4.5 kg/m 2 ; p < 0.001), body weight (−11.7 kg; p < 0.001), waist circumference (−12.6 cm; p < 0.001), and HbA1c (−0.5%; p = 0.033). At ≥ 104 weeks, differences remained for %TWL (−9.1%; p = 0.022) and body weight (−14.6 kg; p = 0.049). In tirzepatide‐only analyses, differences versus MBS were not significant. Among participants with type 2 diabetes, MBS produced greater reductions in BMI, weight, waist, and %TWL, with similar HbA1c improvement.
Conclusions
Both MBS and GLP‐1 RAs provide substantial metabolic benefits. MBS remains superior, but tirzepatide is a promising nonsurgical option supporting personalized obesity care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obesity Unit, Department of General Surgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
- Department of Surgery and Cancer, Imperial Weight Centre, Imperial College Healthcare NHS Trust, London, UK.
- Obesity Unit, Department of Internal Medicine, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
ORCID-Profile: Lucas Sabatella, Nuria Blanco Asensio, Manuel F Landecho
Zitieren
APA
Sabatella, L., Ortega, P. M., Azcárate, V. V., Sastre, F. R., Pagola, A. U., Ahmed, A., Purkayastha, S., Ojanguren, C. T., Asensio, N. B., & Landecho, M. F. (2026). Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP ‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials. Obesity, 34(4), 770-781. https://doi.org/10.1002/oby.70100
Vancouver
Sabatella L, Ortega PM, Azcárate VV, Sastre FR, Pagola AU, Ahmed A, et al. Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP ‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials. Obesity. 2026;34(4):770-781. doi:10.1002/oby.70100
BibTeX
@article{Sabatella2026,
author = {Sabatella, Lucas and Ortega, Patricia M and Azcárate, Víctor Valentí and Sastre, Fernando Rotellar and Pagola, Adriana Uriz and Ahmed, Ahmed and Purkayastha, Sanjay and Ojanguren, Carlota Tuero and Asensio, Nuria Blanco and Landecho, Manuel F},
title = {Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP ‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials},
journal = {Obesity},
year = {2026},
volume = {34},
number = {4},
pages = {770--781},
doi = {10.1002/oby.70100}
}
EUVIMED